










doi:10.101Chronic Kidney Dysfunction in Patients Alive without
Relapse 2 Years after Allogeneic Hematopoietic Stem
Cell Transplantation
Imad Abboud, Raphae¨l Porcher, Marie Robin, Regis Peffault de Latour, Denis Glotz,
Gerard Socie, Marie-Noe¨lle PeraldiAllogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for a wide range of
diseases, but is associated with a significant risk of chronic kidney disease (CKD), affecting up to 25% of
survivors with a significant morbidity. The causes of CKD after HSCT vary between different studies. The
present study evaluated CKD in patients undergoing allogeneic HSCT. We analyzed the clinical course of
148 patients who received allogeneic HSCT at the University Hospital of St. Louis in Paris between 1999
and 2002 and were alive after 2 years without relapse. CKD was defined as a glomerular filtration rate
(GFR)\60 mL/min/1.73 m2, using the abbreviated modification of diet in renal disease (MDRD) equation
for adults and the Schwartz formula for children. Of the 148 relapse-free 2-year survivors, 11 (7%) patients
had renal dysfunction. No chronic renal failure was noted in the younger age group (\15 years at transplan-
tation). CKD was associated with total body irradiation (TBI) (odds ratio [OR] 5 4.53; 95% confidence
interval [CI] 1.15 to 17.9; P 5 .026) and chronic graft-versus-host disease (cGVHD) (OR 5 4.58; 95% CI
1.16-18.1; P 5 .026). Only 1 additional patient developed CKD between 2 and 5 years of follow-up
(cumulative incidence of 0.7% over the 3-year period). In the CKD group, renal function tended to stabilize
over the 3-year period (estimated GFR 456 14 mL/min/1.73 m2 at 2 years and 466 14 mL/min/1.73 m2 at
5 years). A 7% prevalence of CKD was noted in the relapse-free 2-year survivor patients. Renal impairement
was correlated with TBI and cGVHD. Minor incidence of CKD and a relative stability of renal function were
noted between 2 and 5 years after HSCT.
Biol Blood Marrow Transplant 15: 1251-1257 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Allogeneic hematopoietic stem cell transplantation, Chronic kidney disease, GVHD,
NephrotoxicityINTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
is a potentially curative treatment for a wide range of
hematologic, neoplastic, immunologic, and metabolic
diseases. It has improved the prognosis of many
patients worldwide. However, many concerns rise
about the long-term side effects of this therapeutic
procedure. Long-term survivors represent a growing
cohort, and patients older than 60 years old can today
receive HSCT, increasing the risk of occurrence ofDepartment of Nephrology and Transplantation, St.
Hospital, Paris, France.
isclosure: See Acknowledgments on page 1256.
dence and reprint requests: Imad Abboud, MD,
tment of Nephrology and Transplantation, St. Louis
ital, 1 avenue Claude Vellefaux, Paris, France 75010
il: imad.abboud@sls.aphp.fr).
arch 25, 2009; accepted May 26, 2009
erican Society for Blood and Marrow Transplantation
/09/1510-0004$36.00/0
6/j.bbmt.2009.05.016cardiovascular and renal events [1,2]. Among patients
who are free of disease 2 years after transplantation,
the probability of living for 5 more years is 89% [3].
Chronic kidney disease (CKD) is described as
relatively common, affecting around 20% of HSCT
survivors [4,5]. Chronic renal failure (CRF) after suc-
cessful HSCT may diminish the quality of life and
may also lead to end-stage renal disease (ESRD)
requiring chronic dialysis. Patients who develop
ESRD after HSCT have a significantly decreased
survival compared with non-HSCT patients, even
when controlled for comorbidity [6].
CKD after HSCT is commonly attributed to
delayed effects of the radiotherapy used in the condi-
tioning regimen [5,7,8]. A clinical entity called ‘‘bone
marrow transplantation nephropathy’’ was defined by
the association of chronic renal impairement, anemia,
and hypertension [5]. From a histologic point of
view, it was compared to ‘‘radiation nephritis,’’
with extensive mesangiolysis and severe arteriolonec-
rosis [9]. Previous or concurrent chemotherapy may1251
Table 1. Primary Diseases of the 2-Year Relapse-Free Survi-
vors (n 5 148)
Primary Diagnosis N (%)
Malignant Acute leukemia 61 (41%)
Chronic myelogenous leukemia (CML) 22 (15%)
Non-Hodgkin lymphoma 9 (6%)
Myelodysplastic syndrome 8 (6%)
Myeloproliferative syndrome (except CML) 5 (3%)
Nonmalignant Aplastic anemia 27 (18%)
Hemoglobinopathy 11 (7%)
Other 3 (2%)
Autoimmune diseases 1 (1%)
Inborn errors 1 (1%)
1252 Biol Blood Marrow Transplant 15:1251-1257, 2009I. Abboud et al.potentiate the effects of radiation on the kidney. Other
incriminated risk factors for CKD include nephrotoxic
antimicrobials, calcineurin inhibitors (CNIs) used for
the prevention and the treatment of graft-versus-host
disease (GVHD), and GVHD itself [10-16].
The aim of the present study was to evaluate renal
function in long-term disease-free survivors. Among
349 patients who underwent allogeneic HSCT
between 1999 and 2002, we included 148 relapse-
free 2-year survivors to study the CKD prevalence at
2 years after HSCT, and CKD incidence between 2
and 5 years after transplantation.
Our main objective was to identify risk factors
for CKD development in long-term relapse-free
survivors.MATERIALS AND METHODS
A retrospective cohort study design was used for this
study. Between January 1999 and December 2002, 349
patients underwent allogeneic HSCT at the University Hos-
pital of St. Louis in Paris, which serves as a tertiary referral
center for hematologic diseases. We analyzed the clinical
course of the 148 patients who survived at least 2 years after
transplantation without relapse. Data were collected from
patients’ charts.
Adults and children were defined using the threshold of
15 years old at the HSCT day, as in use at our institution.Pre-HSCT Conditioning and GVH Treatments
All the 148 analyzed patients received a conditioning
regimen followed by infusion of donor hematopoietic cells.
Myeloablative (MA) regimens (133 patients; 90%) were typ-
ically cyclophosphamide (Cy)-based (121 patients) with ei-
ther total body irradiation (TBI; 50 patients) or busulfan
(Bu; 63 patients). TBI (12 Gy) was given in six fractions
over 3 days. The kidneys were not shielded. Patients were
considered for nonmyeloablative (NMA) HSCT if they had
hematologic malignancies and were either too old or too ill
to be eligible for conventional MA allogeneic HSCT. NMA
conditioning regimen (15 patients; 10%) consisted of either
fludarabine (Flu; 30 mg/m2/day  3 days) associated with
low-dose TBI (2 Gy in a single fraction) or Flu (25 mg/m2/
day  5 days) associated with Bu (4 mg/kg/day  2 days) or
Cy (60 mg/kg/day  2 day).
Primary diagnoses are presented in Table 1. Patients
were transplanted mainly for acute leukemia (41%), aplastic
anemia (AA; 18%), and chronic myelogenous leukemia
(CML; 15%).
Most patients received transplants from an HLA-
compatible sibling (n5 106, 71%). Others received matched
related (n5 5, 3%) or unrelated (n5 36, 24%) grafts, whereas
only 1 patient received a graft from a monozygotic twin.
The graft was either granulocyte colony-stimulating fac-
tor (G-CSF) mobilized peripheral blood stem cells (PBSCs;
n5 22, 15%), bonemarrow (BM; n5 112, 76%), or cryopre-
served umbilical cord blood (n 5 14, 9%).
The day of stem cell infusion was termed ‘‘day zero,’’ by
convention.Cyclosporine A (CsA) was given asGVHDprophylaxis in
combination with a short course of intravenous (i.v.) metho-
trexate (MTX) in most patients. A few patients received sin-
gle therapy with CsA. After 3 to 6 months the CsA level was
tapered, and withdrawal was initiated between 9 and 12
months in most cases. Prolonged treatment (more than 1
year) was given to patients with chronic GVHD (cGVHD).
Diagnosis and grading of GVHD were performed
according to established criteria [17].
GVHD treatment typically consisted ofmethylpredniso-
lone and resumption of CsA, if already tapered. Five patients
received tacrolimus as the calcineurin inhibitor therapy.
Prophylaxis for infections included acyclovir for herpes
simplex virus (HSV), trimethoprim-sulfamethoxazole to pre-
vent Pneumocystis jirovecii infection, oral fluconazole for pro-
phylaxis of candidal infection, and preemptive ganciclovir for
cytomegalovirus (CMV) disease among viremic patients.
For each studied patient, the following parameters were
collected:
1. Demographic data: age, sex, height, weight.
2. Hematologic data: initial hematologic disease, type of
donor, conditioning regimen (radiation, cytotoxic
therapy, MA versus NMA), GVHD (acute (aGVHD)/
cGVHD, grade/severity, organ involvement, treatment),
hepatic veno-occlusive disease (VOD) (diagnosed accord-
ing to established criteria [18]).
3. Renal data: serum creatinine value the day of transplanta-
tion, 2 years and 5 years after HSCT.Endpoints
CKD was defined as a glomerular filtration rate (GFR)
\60 mL/min/1.73 m2 on at least 2 occasions after 24 months
of relapse-free HSCT, in the range of days 730-1825 post-
transplant. GFR was calculated using the abbreviated modi-







ð0:742 if femaleÞð1:212 if blackÞ;
and the Schwartz formula for children [21].
The time elapsed between the 2 abnormal measurements
was at least 90 days to exclude patients with transient
decreases in GFR.
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Continuous variables are reported as median (interquar-
tile range). For categoric variables the frequency of positive
occurrences are given along with their corresponding
percentages. Characteristics of patients with and without
CKD at 2 years were compared using Fisher’s exact tests.
Cumulative incidence curves of CKD during follow-up
between 2 and 5 years posttransplant were estimated in
patients free of CKD at 2 years, with relapse and death in
remission as competing events.
Reported P-values are 2 sided, and statistical significance
threshold was considered for a value of P\ .05. All analyses
were carried out using R 2.6.2 statistical software (The R
Foundation for Statistical Computing, Vienna, Austria).RESULTS
CKD Prevalence in the Cohort
The study flow chart is described in Figure 1. We
analyzed the clinical course of 148 patients alive and
relapse-free 2 years after HSCT. Among them,
7 patients relapsed before 5 years of follow-up and
8 died. GFR was available before BM transplantation
(BMT) and at 2 years for all patients and at 5 years
for all patients except 1. The median age of the study
cohort at the time of HSCT was 21 years, with a range
of 40 months to 56 years. Seventy-one patients (48%)
were women.
The CKD prevalence at 2 years in relapse-free
survivors was 7% (11 patients). As shown in Figure 1,
CKD is mainly confined to adult population.
Renal Dysfunction at 2 Years
Among the 11 patients with renal impairment at 2
years, estimated GFR was 44 6 14 mL/min/1.73 m2.Figure 1. StudyNo patient had a GFR\60 mL/min/1.73 m2 before
HSCT. The median time to development of CKD
was 8 months (2-20 months) posttransplantation.
One patient suffered hepatic VOD with concomitant
renal impairment. Another patient relapsed between
2 and 5 years after transplantation. None of the
patients needed long-term dialysis nor received a renal
transplant. Three patients recovered a GFR above
60 mL/min/1.73 m2 at 5 years. This renal function im-
provement occurred a long time after CsA withdrawal
in the vast majority of patients, suggesting that it was
independent of CNI-induced vasoconstriction. In the
remaining patients, GFR had recovered slightly after
2 years and remained stable thereafter. Estimated
GFR was 46 6 14 mL/min/1.73 m2 at 5 years for the
11 patients.
In the 11 patients with CKD, 5 patients had mild
hypertension, and urine protein/urine creatinin ratio
ranged from 0.04 to 0.58, demonstrating low-grade
proteinuria. None of the urine samples showed
evidence of hematuria and none of the patients in
this cohort had a renal biopsy for evaluation of CKD
during the study period.
Renal functions were studied in 4 patients and
showed a mainly tubular dysfunction profile compris-
ing a low-molecular weight proteinuria, without a sig-
nificant albuminuria. Mean GFR was 49 mL/min/
1.73 m2 when measured by Cr-EDTA renal clearance.
Renal Dysfunction between 2 and 5 Years after
HSCT
Among patients with no CKD at 2 years (Figure 2),
only 1 patient had CKD appearing between 2 and
5 years after HSCT, corresponding to a cumulative
incidence (CIF) of 0.7% over the 3-year periodflow-chart.
Figure 2. Cumulative incidence of chronic kidney disease (CKD), relapse, and death between 2 and 5 years of follow-up in patients alive, relapse-free,
and CKD-free at 2 years (n 5 137).
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relapsed before 5 years (CIF 4.4% [95% CI 0.9-7.8]),
and 7 patients died free of relapse (CIF 5.1% [95%
CI 1.4-8.8]).
GFR evolution over the 5 years, in patients alive
5 years after HSCT, is shown in Figure 3.
Among 5-year survivors, median estimated GFR
dropped from 107 mL/min per 1.73 m2 before
HSCT to 92 mL/min per 1.73 m2 2 years after
HSCT. After the second year, no further deterioration
of kidney function occurred.Risk Factors for CKD
The baseline characteristics and clinical course of
the 2-year relapse-free survivors were categorized,
based on the development of CKD, as demonstrated
in Table 2.Figure 3. Glomerular filtration rate (GFR) values before HSCT, at 2
and 5 years of follow-up in patients alive at 5 years (n 5 140). Box
and whisker plots present the median, first (box), and third quartile of
the distribution. Horizontal dashed line indicates threshold of CKD.There was an increased risk of CKD at 2 years in
patients who received TBI versus patients who did
not receive TBI (P 5 .026), as well as in patients
with a history of cGVHD (P5 .026). No renal impair-
ment was noted in the younger patients (aged \15
years at transplantation). The primary disease and
the donor type were not associated with the occurence
of late renal dysfunction.
Restricting analysis to adult patients only did not
alter the results, although a not statistically significant
association was found for cGVHD. Actually, when
considering the whole sample, the odds ratios (ORs)
were 4.53 (95% CI 1.15-17.9; P 5 .026) for TBI and
4.58 (1.16-18.1; P 5 .026) for cGVHD, whereas in
the 92 adults only, ORs were 4.86 (1.19-19.8;
P 5 .024) for TBI and 3.58 (0.88-14.6; P 5 .10) for
cGVHD.ORswere thus of similar magnitude, and dif-
ference in statistical tests conclusions may be because
of a loss of power with sample size reduction (92
instead of 148 patients).DISCUSSION
Allogeneic HSCT is an increasingly recognized
treatment for many diseases. More than 20,000 alloge-
neicHSCTprocedures are performed annually around
the world (about 3000 in France), with a 1-year survival
rate of approximately 60% (www.ibmtr.org). In fact,
this therapeutic procedure is associated with a substan-
tial risk of death within the first 2 years after the trans-
plantation [22,23], whereas after 2 years survival curves
often reach a plateau. A previous analysis of data on
6691 patients who were disease-free 2 years after trans-
plantation shows that such patients have an excellent
prognosis [3].
The burden of CKD in the surviving patient pop-
ulation has significant medical and economic implica-
tions given the trend toward increasing longevity in the
Table 2. Patients Alive and Relapse Free at 2 Years: Association of Patient Characteristics with chronic Kidney Disease (CKD) at 2
Years
Variable Median (IQR) GFR before HCT Median (IQR) GFR at 2 years No CKD N 5 137 CKD N 5 11 P-Value
Age .007
#15 years 135 (111-147) 119 (98-146) 57 (42) 0 (0)
>15 years 92 (81-115) 78 (69-95) 80 (58) 11 (100)
Sex >.99
Male 119 (93-137) 102 (80-119) 71 (52) 6 (55)
Female 94 (81-121) 83 (79-100) 66 (48) 5 (45)
Disease .18
Nonmalignant 115 (100-142) 95 (85-128) 42 (31) 1 (9)
Malignant 105 (84-127) 88 (70-107) 95 (69) 10 (91)
Transplant year .52
1999 109 (85-126) 89 (77-104) 23 (17) 2 (18)
2000 106 (91-133) 86 (69-117) 34 (25) 5 (45)
2001 113 (98-126) 92 (76-107) 42 (31) 2 (18)
2002 100 (84-141) 101 (78-128) 38 (28) 2 (18)
Donor type .67
Sibling 108 (85-135) 93 (74-117) 97 (72) 7 (64)
Monozygotic twin 105 99 1 (100) 0 (0)
Other related 114 (110-140) 107 (98-121) 5 (4) 0 (0)
Unrelated 101 (90-122) 87 (70-98) 32 (24) 4 (36)
Cell source .16
BM 109 (89-132) 91 (73-111) 104 (77) 7 (64)
CB 128 (120-149) 103 (90-146) 13 (10) 0 (0)
PBSC 87 (76-102) 83 (65-102) 17 (13) 4 (36)
PBSC + BM 129 133 1 (1) 0 (0)
Conditioning regimen >.99
Nonmyeloablative 82 (69-91) 89 (79-97) 12 (9) 1 (9)
Myeloablative 110 (89-133) 92 (73-113) 123 (91) 10 (91)
TBI .026
No 107 (85-128) 93 (77-117) 85 (63) 3 (27)
Yes 109 (90-135) 89 (69-110) 50 (37) 8 (73)
Acute GVHD (grade) .39
0/I 108 (88-127) 92 (73-112) 97 (72) 6 (55)
II 106 (84-144) 89 (73-110) 33 (25) 5 (45)
III/IV 117 (108-123) 113 (101-127) 4 (3) 0 (0)
Chronic GVHD <2 years .026
No 117 (92-137) 95 (79-119) 79 (63) 3 (27)
Yes 93 (79-115) 85 (69-105) 46 (37) 8 (73)
TBI indicates total body irradiation; GVHD, graft-versus-host disease; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood, GFR, gol-
merular filtration rate; CKD, chronic kidney disease; HSC, hematopoietic stem cell; IQR, interquartile range.
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risk factor for cardiovascular events and end-stage
renal disease.
Renal complications are well described in the early
period after HSCT (first 2 years). Relatively few pub-
lications were interested in the long-term renal
outcome after allogeneic HSCT [24,25], with a me-
dian follow-up generally not exceeding 2 years
[12-14,26,27].
The present study evaluates chronic renal impair-
ment after allogeneic HSCT, unlike other studies, ex-
clusively in patients alive without relapse 2 years after
transplantation, that is, the real long-term survivors.
We did not evaluate patients with autologous
HSCT, because autologous and allogeneic HSCTshould be considered as substantially different entities
in the terms of nephrotoxicity risks.
Our study shows only a 7% prevalence of CKD at
2 years after HSCT in relapse-free survivors. It is
difficult to compare this finding to results of other
studies that dealt with incidence of CKD after
HSCT, that is, taking into account cases of CRF in
patients who died within 2 years after transplantation.
The comparison is also hampered by the fact that
many previous publications studied a cohort of either
auto and allografted patients [13,28].
In addition, many other studies used a Kaplan-
Meier-based statistical description, which may give
an artefactually higher incidence of CKD when
comparing with the cumulative incidence method [29].
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a 14% to 23% cumulative incidence of CKD at 2 years
(27% at 10 years) after MA and NMA [30] allogeneic
HSCT. They identified the following risk factors for
CKD: female sex, older age, and lower GFR pretrans-
plant. Choi et al. [25] showed a 4.4% cumulative inci-
dence of CKD at 5 years after HSCT in 1-year
survivors. We postulate that the differences in preva-
lence between studies may be partially explained by
several factors.
The first factor reflects variable population
characteristics (age, ethnicity, genetic predisposition,
environmental exposition, and underlying disease)
[13,14,24,27,28,31].
The second factor is the period of follow-up.
Another important point could relate to a different
use of CNI. Trough levels of CsA, as well as treatment
duration are rarely described in the different studies
about CKD after HSCT.
Finally, a lower recently reported incidence of
chronic renal disease after HSCT today may be
because of general improvement in patient monitoring
and management.
Another relevant point in our study is the stable
kidney function between 2 and 5 years after allogeneic
HSCT. This information is in agreement with
previous studies [28,31,32].
Chronic renal insufficiency following HSCT in
children as well as in adults has predominantly been
associated with TBI [4,5,9-11,31,33-36]. This is in ac-
cordance with our findings. A dose-effect relationship
has been shown in adult patients receiving TBI with
higher degrees of renal shielding, resulting in signifi-
cantly lower rates of BMT nephropathy [37,38].
We were not able to reproduce the same observa-
tion in the present study because the vast majority of
our patients received the same radiation protocol and
no patient had renal shielding.
Noteworthy, many studies reported high inci-
dences of CKD after NMA HSCT [26,30] (from 20%
to 66%, depending on the used definition criteria
[14]), although using a low dose of TBI. This apparent
discrepancywith theobservationofTBIdose-nephrop-
athy relationship is probably explained by other renal
risk factors in this selected population (age, comorbid-
ities, etc.), as stated byWeiss et al. [14]. The latter series
mainly included early renal failure (1-year follow-up)
and mixed aGVHD and cGVHD.
In accordance with many other reports in the liter-
ature [11,13,14,26], we found that cGVHD is associ-
ated with CKD. Miralbell et al. [11] observed
a direct association between the presence of GVHD
and treatment intensity with potentially nephrotoxic
drugs, thus implying that renal dysfunction might be
related to nephrotoxic drug administration, but not
directly to GVHD status. However, a specific
allogeneic-induced renal disease cannot be excluded,especially in light of many publications on GVHD-
associated glomerulopathies [39,40].
CNIs are the cornerstone of therapy for GVHD.
We think that CNI levels are higly variable and their
use is often discontinuous, making it very difficult to
precisely quantify organ exposure to these nephrotoxic
drugs. In addition, CNI long-term use after allogeneic
HSCT is mainly confined to cGVHD patients. Thus,
long-term use of calcineurin inhibitors and cGVHD
werenot considered as separate variables inour analysis.
The results of our study should be interpreted with
the following limitations in mind.
First, the study size is relatively small, with data
from a single center. Second, data were collected by
chart review. Third, we did not have data on urine
characteristics such as protein excretion for many
patients, and no kidney biopsy was available to further
help understand the type and etiology of CKD.
In summary, this study describes the occurrence of
CKD after allogeneic HSCT in 2 years relapse-free
survivors and supports conclusions fromprevious stud-
ies that TBI and GVHD influence the development of
CKD after HSCT.
Chronic renal insufficiency following BMT
remains a great challenge facing the nephrology and
oncology community today. Future long-term
follow-up studies with better characterization of renal
parameters will be needed.ACKNOWLEDGMENTS
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